%0 Journal Article
%T 何时应用大剂量阿糖胞苷对急性髓系白血病患者最有利?<br>When is the optimal time of high-dose cytarabine for patients with acute myeloid leukemia?
%A 庞艳彬
%A 任 杰
%A 范丽霞
%A 李文文
%A 田明杰
%A 罗建民
%A 杜 欣
%J 医学争鸣
%D 2017
%X 虽然大部分临床医生认为4个疗程大剂量阿糖胞苷（high-dose cytarabine，HDAC）的治疗方案是急性 髓系白血病（acute myeloid leukemia，AML）患者（年龄＜60岁）的最佳治疗方案，其结果有利于提高患者的总生 存期和无病生存期，其原因可能是基于早期HDAC的临床试验结果。然而近期有关临床试验对这种认识提出了质 疑，有实验表明HDAC作为AML的巩固治疗增加了患者的毒性反应，但并没有明显增强抗肿瘤的效应。产生这种 差异的原因除因不同实验组间使用的阿糖胞苷（cytarabine，Ara-C）剂量以及与不同的联合药物有关以外，还可能 与不同实验组之间使用HDAC的时机上存在差异有关。因此，我们对HDAC的临床试验结果进行重新分析，以明确 何时应用何种计量的Ara-C对AML患者最有利。<br>Most physicians believe that four courses of consolidation therapy with high-dose cytarabine (HDAC) is optimal for patients with acute myeloid leukemia (AML) who are younger than 60 years of age. Their belief probably comes from early studies that have established the use of HDAC in first-line treatment. Recent evidence has challenged the need for these exceptionally high-dose levels of cytarabine, which reports that induction therapy with HDAC results in excessive toxic effects without conferring increased antileukemic effects. The reasons for this discrepancy may be involved in the use of different doses and schedules of cytarabine in combination with different drugs by different investors, but more importantly, they are associated with the time point at which patients receive their programs containing HDAC. To determine when to use and what kind of measurement of the dose of cytarabine that are most beneficial for patients with AML, we present a reappraisal of the use of HDAC for AML treatment
%K 大剂量阿糖胞苷
%K 急性髓系白血病
%K 总生存期
%K 无病生存期<br>high-dose cytarabine
%K acute myeloid leukemia
%K overall survival
%K disease-free survival
%U http://yxzm.paperonce.org/oa/DArticle.aspx?type=view&id=201706008